Tags

Type your tag names separated by a space and hit enter

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
Eur Respir J. 2005 Aug; 26(2):214-22.ER

Abstract

This study compared the bronchodilator effects of tiotropium, formoterol and both combined in chronic obstructive pulmonary disease (COPD). A total of 71 COPD patients (mean forced expiratory volume in one second (FEV1) 37% predicted) participated in a randomised, double-blind, three-way, crossover study and received tiotropium 18 microg q.d., formoterol 12 microg b.i.d. or both combined q.d. for three 6-week periods. The end-points were 24-h spirometry (FEV1, forced vital capacity (FVC)) at the end of each treatment, rescue salbutamol and safety. Compared with baseline (FEV1 prior to the first dose in the first period), tiotropium produced a significantly greater improvement in average daytime FEV1 (0-12 h) than formoterol (127 versus 86 mL), while average night-time FEV1 (12-24 h) was not different (tiotropium 43 mL, formoterol 38 mL). The most pronounced effects were provided by combination therapy (daytime 234 mL, night-time 86 mL); both differed significantly from single-agent therapies. Changes in FVC mirrored the FEV1 results. Compared with both single agents, daytime salbutamol use was significantly lower during combination therapy (tiotropium plus formoterol 1.81 puffs.day(-1), tiotropium 2.41 puffs x day(-1), formoterol 2.37 puffs x day(-1)). All treatments were well tolerated. In conclusion, in chronic obstructive pulmonary disease patients, tiotropium q.d. achieved a greater improvement in daytime and comparable improvement in night-time lung function compared with formoterol b.i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval.

Authors+Show Affiliations

Dept of Respiratory Diseases, Atrium medisch centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands. j.a.vannoord@atriummc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16055868

Citation

van Noord, J A., et al. "Comparison of Tiotropium once Daily, Formoterol Twice Daily and Both Combined once Daily in Patients With COPD." The European Respiratory Journal, vol. 26, no. 2, 2005, pp. 214-22.
van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214-22.
van Noord, J. A., Aumann, J. L., Janssens, E., Smeets, J. J., Verhaert, J., Disse, B., Mueller, A., & Cornelissen, P. J. (2005). Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. The European Respiratory Journal, 26(2), 214-22.
van Noord JA, et al. Comparison of Tiotropium once Daily, Formoterol Twice Daily and Both Combined once Daily in Patients With COPD. Eur Respir J. 2005;26(2):214-22. PubMed PMID: 16055868.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. AU - van Noord,J A, AU - Aumann,J-L, AU - Janssens,E, AU - Smeets,J J, AU - Verhaert,J, AU - Disse,B, AU - Mueller,A, AU - Cornelissen,P J G, PY - 2005/8/2/pubmed PY - 2006/9/29/medline PY - 2005/8/2/entrez SP - 214 EP - 22 JF - The European respiratory journal JO - Eur. Respir. J. VL - 26 IS - 2 N2 - This study compared the bronchodilator effects of tiotropium, formoterol and both combined in chronic obstructive pulmonary disease (COPD). A total of 71 COPD patients (mean forced expiratory volume in one second (FEV1) 37% predicted) participated in a randomised, double-blind, three-way, crossover study and received tiotropium 18 microg q.d., formoterol 12 microg b.i.d. or both combined q.d. for three 6-week periods. The end-points were 24-h spirometry (FEV1, forced vital capacity (FVC)) at the end of each treatment, rescue salbutamol and safety. Compared with baseline (FEV1 prior to the first dose in the first period), tiotropium produced a significantly greater improvement in average daytime FEV1 (0-12 h) than formoterol (127 versus 86 mL), while average night-time FEV1 (12-24 h) was not different (tiotropium 43 mL, formoterol 38 mL). The most pronounced effects were provided by combination therapy (daytime 234 mL, night-time 86 mL); both differed significantly from single-agent therapies. Changes in FVC mirrored the FEV1 results. Compared with both single agents, daytime salbutamol use was significantly lower during combination therapy (tiotropium plus formoterol 1.81 puffs.day(-1), tiotropium 2.41 puffs x day(-1), formoterol 2.37 puffs x day(-1)). All treatments were well tolerated. In conclusion, in chronic obstructive pulmonary disease patients, tiotropium q.d. achieved a greater improvement in daytime and comparable improvement in night-time lung function compared with formoterol b.i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval. SN - 0903-1936 UR - https://www.unboundmedicine.com/medline/citation/16055868/Comparison_of_tiotropium_once_daily_formoterol_twice_daily_and_both_combined_once_daily_in_patients_with_COPD_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=16055868 DB - PRIME DP - Unbound Medicine ER -